FDA approvals

Biotech

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the industry has closed the year with a powerful rally, fueled by a dovish shift from the Federal Reserve and

Biotech

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts by surprise. After years of trading in the shadow of high interest rates and regulatory uncertainty, the industry